Patents by Inventor Magid A. Abou-Gharbia

Magid A. Abou-Gharbia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200392073
    Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.
    Type: Application
    Filed: May 24, 2017
    Publication date: December 17, 2020
    Inventors: Magid A. Abou-Gharbia, Wayne E. Childers, Marlene A. Jacobson, Rong Fan, Rogelio L. Martinez
  • Publication number: 20200354307
    Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.
    Type: Application
    Filed: November 20, 2018
    Publication date: November 12, 2020
    Inventors: Edward G. Melenski, Wayne E. Childers, Marlene A. Jacobson, Magid A. Abou-Gharbia
  • Publication number: 20200317648
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 8, 2020
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Patent number: 10759750
    Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: September 1, 2020
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: Magid A. Abou-Gharbia, Benjamin E. Blass, Wayne E. Childers, Mercy Ramanjulu, George C. Morton
  • Publication number: 20200223810
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Patent number: 10676464
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: June 9, 2020
    Assignee: Temple University Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Publication number: 20200071314
    Abstract: The present invention includes novel aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 5, 2020
    Inventors: Jean-Pierre J. Issa, Hanghang Zhang, Magid Abou-Gharbia, Wayne E. Childers, George C. Morton
  • Patent number: 10544117
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: January 28, 2020
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Publication number: 20190367493
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: May 14, 2019
    Publication date: December 5, 2019
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • Publication number: 20190352272
    Abstract: The present invention includes novel bridged bicycloalkyl-substituted aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 21, 2019
    Inventors: Wayne C. Childers, Magid A. Abou-Gharbia, George C. Morton, Jean-Pierre J. Issa, Hanghang Zhang
  • Patent number: 10287274
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: May 14, 2019
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Publication number: 20190127323
    Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.
    Type: Application
    Filed: April 27, 2017
    Publication date: May 2, 2019
    Inventors: Magid A. Abou-Gharbia, Benjamin E. Blass, Wayne E. Childers, Mercy Ramanjalu, George C. Morton
  • Patent number: 10239868
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 26, 2019
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Patent number: 10131637
    Abstract: Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 20, 2018
    Assignees: Shifa Biomedical Corporation, Temple University—Of The Commonwealth System of Higher Education
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Patent number: 9975879
    Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: May 22, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Magid Abou-Gharbia, Wayne E. Childers, Rogelio L. Martinez, Mercy M. Ramanjulu, Benjamin E. Blass
  • Publication number: 20180079730
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 22, 2018
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Publication number: 20180016262
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • Publication number: 20180016261
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • Patent number: 9802924
    Abstract: Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 31, 2017
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Publication number: 20170298037
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 19, 2017
    Applicant: Temple University-Of the Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia